Consensus Recommendations for Hyperpolarized [1-13C]pyruvate MRI Multi-center Human Studies
Authors:
Shonit Punwani,
Peder EZ Larson,
Christoffer Laustsen,
Jan VanderMeulen,
Jan Henrik Ardenkjær-Larsen,
Adam W. Autry,
James A. Bankson,
Jenna Bernard,
Robert Bok,
Lotte Bonde Bertelsen,
Jenny Che,
Albert P. Chen,
Rafat Chowdhury,
Arnaud Comment,
Charles H. Cunningham,
Duy Dang,
Ferdia A Gallagher,
Adam Gaunt,
Yangcan Gong,
Jeremy W. Gordon,
Ashley Grimmer,
James Grist,
Esben Søvsø Szocska Hansen,
Mathilde Hauge Lerche,
Richard L. Hesketh
, et al. (17 additional authors not shown)
Abstract:
Magnetic resonance imaging of hyperpolarized (HP) [1-13C]pyruvate allows in-vivo assessment of metabolism and has translated into human studies across diseases at 15 centers worldwide. Consensus on best practice for multi-center studies is required to develop clinical applications. This paper presents the results of a 2-round formal consensus building exercise carried out by experts with HP [1-13C…
▽ More
Magnetic resonance imaging of hyperpolarized (HP) [1-13C]pyruvate allows in-vivo assessment of metabolism and has translated into human studies across diseases at 15 centers worldwide. Consensus on best practice for multi-center studies is required to develop clinical applications. This paper presents the results of a 2-round formal consensus building exercise carried out by experts with HP [1-13C]pyruvate human study experience. Twenty-nine participants from 13 sites brought together expertise in pharmacy methods, MR physics, translational imaging, and data-analysis; with the goal of providing recommendations and best practice statements on conduct of multi-center human studies of HP [1-13C]pyruvate MRI.
Overall, the group reached consensus on approximately two-thirds of 246 statements in the questionnaire, covering 'HP 13C-Pyruvate Preparation', 'MRI System Setup, Calibration, and Phantoms', 'Acquisition and Reconstruction', and 'Data Analysis and Quantification'.
Consensus was present across categories, examples include that: (i) different HP pyruvate preparation methods could be used in human studies, but that the same release criteria have to be followed; (ii) site qualification and quality assurance must be performed with phantoms and that the same field strength must be used, but that the rest of the system setup and calibration methods could be determined by individual sites; (iii) the same pulse sequence and reconstruction methods were preferable, but the exact choice should be governed by the anatomical target; (iv) normalized metabolite area-under-curve (AUC) values and metabolite AUC were the preferred metabolism metrics.
The work confirmed areas of consensus for multi-center study conduct and identified where further research is required to ascertain best practice.
△ Less
Submitted 29 April, 2025;
originally announced April 2025.
Advanced Simulation of Droplet Microfluidics
Authors:
Andreas Grimmer,
Medina Hamidović,
Werner Haselmayr,
Robert Wille
Abstract:
The complexity of droplet microfluidics grows by implementing parallel processes and multiple functionalities on a single device. This poses a challenge to the engineer designing the microfluidic networks. In today's design processes, the engineer relies on calculations, assumptions, simplifications, as well as his/her experiences and intuitions. In order to validate the obtained specification of…
▽ More
The complexity of droplet microfluidics grows by implementing parallel processes and multiple functionalities on a single device. This poses a challenge to the engineer designing the microfluidic networks. In today's design processes, the engineer relies on calculations, assumptions, simplifications, as well as his/her experiences and intuitions. In order to validate the obtained specification of the microfluidic network, usually a prototype is fabricated and physical experiments are conducted thus far. In case the design does not implement the desired functionality, this prototyping iteration is repeated - obviously resulting in an expensive and time-consuming design process. In order to avoid unnecessary prototyping loops, simulation methods could help to validate the specification of the microfluidic network before any prototype is fabricated. However, state-of-the-art simulation tools come with severe limitations, which prevent their utilization for practically-relevant applications. More precisely, they are often not dedicated to droplet microfluidics, cannot handle the required physical phenomena, are not publicly available, and can hardly be extended. In this work, we present an advanced simulation approach for droplet microfluidics which addresses these shortcomings and, eventually, allows to simulate practically-relevant applications. To this end, we propose a simulation framework which directly works on the specification of the design, supports essential physical phenomena, is publicly available, and easy to extend. Evaluations and case studies demonstrate the benefits of the proposed simulator: While current state-of-the-art tools were not applicable for practically-relevant microfluidic networks, the proposed solution allows to reduce the design time and costs e.g. of a drug screening device from one person month and USD 1200, respectively, to just a fraction of that.
△ Less
Submitted 2 October, 2018;
originally announced October 2018.
